Company Filing History:
1 out of 2 
1 out of 55 
1 out of 2 
Years Active: 2023
Title: The Innovations of Gilles Avenard
Introduction
Gilles Avenard is a notable inventor based in Montrouge, France. He has made significant contributions to the field of biotechnology, particularly in the area of platelet aggregation. His work has implications for treating various medical conditions related to Glycoprotein VI.
Latest Patents
Avenard holds a patent titled "Inhibition of platelet aggregation using anti-human GPVI antibodies." This invention involves an isolated humanized protein that binds to human Glycoprotein VI (hGPVI) for treating GPVI-related conditions. The isolated humanized protein is designed to be administered to a subject for a duration of at least 2 hours, preferably between 4 to 6 hours.
Career Highlights
Throughout his career, Gilles Avenard has worked with prominent organizations such as Acticor Biotech and Université Paris Cité. His experience in these institutions has allowed him to advance his research and contribute to innovative solutions in the medical field.
Collaborations
Avenard has collaborated with esteemed colleagues, including Philippe Billiald and Martine Jandrot-Perrus. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking inventions.
Conclusion
Gilles Avenard's work exemplifies the impact of innovation in biotechnology. His patent on inhibiting platelet aggregation showcases his commitment to advancing medical treatments. Through his career and collaborations, Avenard continues to contribute to significant advancements in healthcare.